Propranolol
Indications
Propranolol was the first clinically successful beta-blocker and remains one of the most versatile drugs in pharmacology, with FDA-approved indications spanning cardiology, neurology, endocrinology, and paediatric dermatology. As a non-selective antagonist of both β1 and β2 receptors, it has a broader effect profile than the cardioselective beta-blockers (metoprolol, bisoprolol, atenolol), making it especially useful for indications where peripheral β2 blockade is therapeutic — essential tremor, migraine prophylaxis, performance anxiety, and infantile haemangioma — but also more likely to cause bronchospasm and unmasked vasoconstriction.
| Indication | Population / Formulation | Therapy Type | Status |
|---|---|---|---|
| Hypertension — to lower blood pressure and reduce cardiovascular events | Adults; all oral formulations (Inderal, Inderal LA, Inderal XL, InnoPran XL) | Monotherapy or combination, particularly with thiazide diuretic | FDA Approved |
| Angina pectoris — long-term management of chronic stable angina due to coronary atherosclerosis | Adults; Inderal (IR) and Inderal LA | Monotherapy or with nitrates / calcium channel blockers | FDA Approved |
| Atrial fibrillation — control of ventricular rate; also for atrial flutter, supraventricular tachycardia, and digitalis-induced tachyarrhythmias | Adults; Inderal (IR oral and IV) | Monotherapy or with digoxin / non-DHP CCB | FDA Approved |
| Myocardial infarction — to reduce cardiovascular mortality after recent MI | Adults who survived the acute phase; Inderal (IR) | Long-term post-MI secondary prevention | FDA Approved |
| Migraine prophylaxis — prevention of common (episodic) migraine | Adults; Inderal (IR) and Inderal LA | Adjunct to lifestyle modification and trigger avoidance | FDA Approved (AAN Level A) |
| Essential tremor — familial or hereditary essential tremor | Adults; Inderal (IR) | First-line pharmacotherapy (with primidone) | FDA Approved |
| Hypertrophic obstructive cardiomyopathy (hypertrophic subaortic stenosis) — symptomatic relief of dynamic LV outflow obstruction | Adults; Inderal (IR) | First-line pharmacotherapy for symptomatic HOCM | FDA Approved |
| Pheochromocytoma — adjunctive control of tachycardia and tremor during preoperative management or in inoperable patients | Adults; Inderal (IR) — only after adequate alpha-blockade is established | Adjunct to alpha-adrenergic blocker | FDA Approved |
| Proliferating infantile haemangioma requiring systemic therapy | Infants 5 weeks to 5 months at initiation; Hemangeol oral solution | First-line systemic therapy | FDA Approved (2014; Hemangeol) |
| Performance anxiety / situational anxiety — symptom-targeted use for somatic anxiety | Adults; Inderal (IR), low intermittent doses | As-needed before triggering events | Off-Label (widely used) |
| Variceal bleeding prophylaxis in cirrhosis | Adults with documented oesophageal varices | Primary or secondary prophylaxis (alternative to carvedilol) | Off-Label (guideline-supported) |
| Thyrotoxicosis / thyroid storm — symptomatic adrenergic control | Adults; Inderal (IR oral and IV) | Adjunct to definitive thyroid therapy | Off-Label (well-established) |
| Antipsychotic-induced akathisia | Adults; Inderal (IR), low doses | First-line pharmacotherapy | Off-Label (clinically established) |
| Post-traumatic stress disorder (PTSD) — adjunctive symptom management | Adults | Adjunct to standard PTSD therapy | Off-Label (limited evidence) |
The breadth of propranolol’s indication list reflects its mechanistic versatility: peripheral β2 blockade addresses physical anxiety symptoms (tremor, palpitations) and tremor itself; central CNS penetration mediates migraine prophylaxis (mechanism incompletely understood); and the unique 2014 paediatric approval for infantile haemangioma (Hemangeol) followed the serendipitous 2008 observation by Léauté-Labrèze and colleagues that an infant treated for cardiomyopathy showed dramatic regression of a facial haemangioma. Hemangeol is the only FDA-approved systemic therapy for proliferating infantile haemangioma.
Performance anxiety — propranolol 10–40 mg taken 30–60 minutes before a triggering event blunts the somatic adrenergic response (tachycardia, tremor) without sedation. Particularly useful for musicians, public speakers, and surgical trainees. Evidence quality: moderate (small trials).
Variceal bleeding prophylaxis — non-selective beta-blockade reduces portal pressure via splanchnic vasoconstriction (β2 effect) and decreased cardiac output. Evidence quality: high (long-standing guideline support).
Akathisia (antipsychotic-induced) — propranolol 30–80 mg/day in divided doses is frequently first-line; benztropine is preferred for parkinsonism. Evidence quality: moderate.
Thyroid storm — propranolol 60–80 mg PO every 4 hours, or 0.5–1 mg IV slow push (titrated cautiously); also has weak inhibitory effect on peripheral T4-to-T3 conversion. Evidence quality: high (standard of care).
Dosing
| Clinical Scenario | Starting Dose | Titration / Maintenance | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — adult, immediate-release (Inderal) | 40 mg PO twice daily (alone or added to a diuretic) | Increase gradually; usual maintenance 120–240 mg/day in 2–3 divided doses | 640 mg/day | Twice-daily dosing typically sufficient; some patients require TID dosing for 24-hour control Full antihypertensive response may take several weeks |
| Hypertension — adult, long-acting (Inderal LA) | 80 mg PO once daily | Maintenance 120–160 mg once daily | 640 mg/day | Once-daily dosing supports adherence; equivalent total daily dose to IR |
| Hypertension — adult, extended-release (InnoPran XL / Inderal XL) | 80 mg PO once daily at bedtime (~10 p.m.) | May increase every 2–3 weeks; maintenance 80–120 mg/day | 120 mg/day | Bedtime dosing produces peak plasma levels in the early morning, targeting the morning BP surge Doses above 120 mg confer no additional BP-lowering effect per the Inderal XL PI |
| Chronic stable angina — adult, IR | 10–20 mg PO three times daily (or 80 mg LA once daily) | Increase weekly; usual range 80–320 mg/day in 2–4 divided doses | 320 mg/day | Resting heart rate target generally 55–60 bpm |
| Atrial arrhythmias / SVT — IV (acute) | 1–3 mg IV slow push at maximum rate of 1 mg/minute | May repeat after 2 minutes; subsequent doses no sooner than every 4 hours | Typically 5 mg cumulative in acute setting | Continuous ECG and BP monitoring; have atropine, fluids, glucagon available Transition to oral therapy as soon as feasible |
| Atrial arrhythmias / SVT — oral, IR | 10–30 mg PO three to four times daily before meals and at bedtime | Titrate to rate control and symptom relief | Per indication and tolerability | For chronic AF rate control, total daily doses of 80–240 mg are common |
| Post-MI mortality reduction — adult, IR | 40 mg PO three times daily initially | Increase to 60–80 mg three times daily as tolerated; total daily dose 180–240 mg in 3–4 divided doses | 240 mg/day per the Inderal PI for this indication | Begin in early convalescence (typically 5–21 days post-infarction). Patients are generally transitioned to a once-daily long-acting beta-blocker for chronic post-MI therapy Cardioselective agents (metoprolol succinate, bisoprolol) are now usually preferred |
| Migraine prophylaxis — adult, IR | 80 mg/day PO in divided doses (or 80 mg LA once daily) | Increase gradually; usual range 160–240 mg/day | 240 mg/day per the Inderal PI for this indication | If satisfactory response not seen within 4–6 weeks at the maximum tolerated dose, discontinue gradually |
| Essential tremor — adult, IR | 40 mg PO twice daily | Increase as tolerated; usual maintenance 120–320 mg/day in divided doses | 320 mg/day per the Inderal PI for this indication | Best response often at 80–160 mg/day; primidone is the alternative first-line agent |
| Hypertrophic obstructive cardiomyopathy — adult, IR | 20–40 mg PO three to four times daily before meals and at bedtime | Titrate to symptom relief | Per tolerability | Higher doses than for hypertension may be needed |
| Pheochromocytoma (preoperative) — adult, IR | 60 mg/day PO in divided doses for 3 days before surgery | Adjusted to control tachycardia and tremor | Per tolerability | Only after adequate alpha-blockade is established — beta-blocker alone causes paradoxical hypertension. For inoperable malignant pheochromocytoma: ~30 mg/day in divided doses |
| Performance / situational anxiety (off-label) | 10–40 mg PO taken 30–60 minutes before the triggering event | Adjust based on response and tolerability for future events | Use intermittent dosing; not for daily/chronic anxiety | Lowest effective dose; avoid if asthma history |
| Akathisia — adult, IR (off-label) | 10–20 mg PO three times daily | Titrate to symptom relief; usual range 30–80 mg/day | 120 mg/day | Onset of relief typically within hours to days |
| Variceal bleeding prophylaxis — adult, IR (off-label) | 20 mg PO twice daily | Titrate to ~25% reduction in resting HR or HR ~55 bpm; usual range 40–160 mg/day | 320 mg/day | Carvedilol is increasingly preferred per current guidance; nadolol is an equivalent non-selective alternative |
| Thyroid storm — adult, IR oral or IV (off-label) | PO: 60–80 mg every 4 hours IV: 0.5–1 mg slow IV push with continuous monitoring | Titrate to HR and adrenergic symptom control | Per haemodynamics | Caution in patients with thyroid-storm-related cardiomyopathy (may precipitate decompensation) |
| Proliferating infantile haemangioma — Hemangeol oral solution | 0.6 mg/kg twice daily (0.15 mL/kg of 4.28 mg/mL solution), at least 9 hours apart | Week 2: increase to 1.1 mg/kg twice daily Week 3 onward: 1.7 mg/kg twice daily for 6 months total | 1.7 mg/kg twice daily (3.4 mg/kg/day) | Initiate at 5 weeks to 5 months of age; not for infants <2 kg or <5 weeks corrected age. Give during or right after a feeding to reduce hypoglycaemia risk; skip dose if not feeding or vomiting Monitor HR and BP for 2 hours after first dose and after each dose increase. Generic oral propranolol (4 or 8 mg/mL) is also widely used at 1–3 mg/kg/day in divided doses but requires careful prescribing to avoid concentration-related dosing errors |
| Discontinuation | Reduce gradually over 1–2 weeks (typical halving every 3–7 days) | Abrupt withdrawal may exacerbate ischaemia, precipitate MI in CAD, cause rebound tachycardia/hypertension, or precipitate thyroid storm in thyrotoxic patients | ||
Population-Specific Considerations
| Population | Adjustment | Rationale |
|---|---|---|
| Renal impairment | Use with caution | Less than 1% excreted unchanged; metabolites have minimal beta-blocking activity. Use cautiously per the Inderal PI; not significantly removed by haemodialysis |
| Hepatic impairment | Initiate at lower doses; titrate gradually | Extensive first-pass hepatic metabolism — bioavailability and plasma levels increase substantially with hepatic dysfunction |
| Elderly | Lower starting dose; cautious titration | Per the Inderal PI: greater frequency of decreased hepatic, renal, or cardiac function; concomitant disease and drug therapy |
| Paediatric (general indications) | Safety and effectiveness not established for adult cardiovascular indications | Bronchospasm and congestive heart failure have been reported coincident with paediatric administration per the Inderal PI |
| Paediatric (infantile haemangioma) | Hemangeol per body weight as above; do not use in infants <2 kg or <5 weeks corrected age | FDA-approved indication with age- and weight-specific labelling |
| CYP2D6 poor metabolisers | Expect higher exposure; cautious titration | Multiple metabolic pathways (CYP2D6, 1A2, 2C19) provide some compensation, but propranolol exposure is meaningfully higher in CYP2D6 poor metabolisers |
| Pregnancy | Use only if benefit clearly outweighs risk | Crosses placenta; reports of intrauterine growth retardation, small placentas, congenital abnormalities. Neonatal monitoring at delivery for bradycardia, hypoglycaemia, and respiratory depression |
For chronic indications (hypertension, migraine prophylaxis, essential tremor, post-MI), once-daily long-acting formulations (Inderal LA, Inderal XL, InnoPran XL) generally improve adherence over IR. InnoPran XL is uniquely designed for bedtime dosing with peak plasma concentrations 12–14 hours later — useful for patients with prominent morning blood-pressure surge. For acute or rapidly titrated indications (acute arrhythmia, thyroid storm, situational anxiety, hospitalised patients), the IR tablet or IV preparation is preferred. For infantile haemangioma, Hemangeol is the only formulation with FDA approval for this indication and pre-validated paediatric concentration (4.28 mg/mL); generic oral solutions exist in two concentrations (4 mg/mL and 8 mg/mL) and require careful prescribing to avoid dosing errors.
Pharmacology
Mechanism of Action
Propranolol is a non-selective competitive antagonist at both β1- and β2-adrenergic receptors, with no intrinsic sympathomimetic activity and no significant alpha-adrenergic effect at clinical doses. β1 blockade in the heart reduces resting and exercise heart rate, slows AV nodal conduction, and decreases myocardial contractility — together lowering cardiac output and myocardial oxygen demand. β2 blockade in vascular smooth muscle, bronchi, and metabolic tissues accounts for distinctive features of propranolol versus cardioselective agents: cold extremities and peripheral vasoconstriction; bronchospasm in susceptible patients; impaired hypoglycaemic counter-regulation; reduced essential and physiological tremor; and reduced portal pressure in cirrhotic varices via splanchnic vasoconstriction.
Membrane-stabilising activity is detectable only at concentrations far above those needed for beta-blockade and is not clinically relevant. Propranolol is highly lipophilic, crosses the blood-brain barrier readily, and exerts central effects implicated in its efficacy for migraine prophylaxis, essential tremor, performance anxiety, and akathisia. The mechanism by which propranolol promotes regression of infantile haemangiomas is incompletely understood; proposed mechanisms include vasoconstriction, inhibition of angiogenesis (via downregulation of VEGF and bFGF), and induction of apoptosis in capillary endothelial cells.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly and almost completely absorbed orally; absolute bioavailability ~25% due to extensive first-pass hepatic metabolism. Peak plasma concentrations within 1–4 hours for IR; for InnoPran XL given at 10 p.m., steady-state Tmax 12–14 hours after dosing. Food may increase bioavailability of IR by reducing first-pass extraction | Substantial inter-patient variability in plasma levels with the same oral dose. The IV-to-oral dose ratio is approximately 1:10 because of first-pass metabolism |
| Distribution | Approximately 90% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Highly lipophilic — readily crosses the blood-brain barrier with appreciable CSF concentrations; also crosses the placenta and is excreted in breast milk | CNS penetration accounts for fatigue, vivid dreams, depressive symptoms, and the central efficacy in migraine and tremor. The high protein binding is rarely clinically meaningful but is relevant in severe hypoalbuminaemia |
| Metabolism | Extensively metabolised in the liver via CYP2D6, CYP1A2, and CYP2C19. Primary metabolites include 4-hydroxypropranolol (active) and naphthyloxylactic acid. Multiple metabolic pathways provide partial protection against any single CYP inhibitor or polymorphism | Strong inhibitors of CYP2D6 (paroxetine, fluoxetine, bupropion, quinidine), CYP1A2 (cimetidine, fluvoxamine, ciprofloxacin, smoking cessation), or CYP2C19 (fluvoxamine, fluconazole) raise propranolol exposure. Inducers of CYP1A2 (smoking, rifampicin) or CYP2C19 (rifampicin) lower exposure |
| Elimination | Plasma half-life 3–6 hours for IR; ~8 hours for InnoPran XL; 8–11 hours for sustained-release formulations. Less than 1% of an oral dose is excreted unchanged in urine — propranolol is essentially eliminated as inactive or partly active metabolites. Not significantly dialysable | No renal dose adjustment generally needed. Hepatic impairment substantially raises exposure — initiate at lower dose. The longer apparent half-life of LA/XR formulations reflects sustained release rather than slower elimination |
Propranolol’s non-selectivity is both its strength and its limitation. The β2 effect underlies several distinctive therapeutic uses (essential tremor, migraine, performance anxiety, variceal prophylaxis, infantile haemangioma) and several distinctive adverse effects (bronchospasm, peripheral vasoconstriction, exaggerated hypoglycaemic episodes). For patients in whom the β1 cardiac effect is the primary therapeutic goal — chronic heart failure, isolated hypertension in patients with reactive airways disease, diabetics — a cardioselective beta-blocker (metoprolol succinate, bisoprolol) is generally preferred. Propranolol’s CNS penetration also makes it more likely than less-lipophilic agents (atenolol, nadolol) to cause fatigue, sleep disturbance, vivid dreams, and depressive symptoms.
Side Effects
Propranolol’s adverse-effect profile reflects β1 (cardiac) antagonism, β2 (peripheral and metabolic) antagonism, and prominent CNS penetration. The Inderal prescribing information notes that “the following adverse reactions have been observed, but there is not enough systematic collection of data to support an estimate of their frequency” — historic clinical-trial reporting predates the modern requirement for tabulated incidence rates. Specific quantitative rates below are drawn from the InnoPran XL PI (Table 1, ≥3% reporting threshold) and from the Hemangeol paediatric trials. Most adverse effects are mild and transient.
| Adverse Effect | Reported Incidence | Clinical Note |
|---|---|---|
| Fatigue | Common (≥3%) | Often dose-related; may improve over the first 2–4 weeks. A common reason for early discontinuation; consider lowering dose before stopping. |
| Dizziness | Common (≥3%) | Frequently orthostatic; counsel patients to rise slowly. More common at initiation and after dose increases. |
| Bradycardia | Common (≥3%) | Symptomatic if HR <50 bpm or accompanied by hypotension; reduce dose or discontinue. |
| Cold extremities | Common (β2-mediated) | Reflects loss of β2-mediated peripheral vasodilatation; more common with non-selective agents than with cardioselective beta-blockers. |
| Headache, insomnia, vivid dreams, nightmares | CNS-penetrant beta-blocker class effect | Switching to a less lipophilic agent (atenolol, nadolol) may help; bedtime dosing of long-acting formulations occasionally helps. |
| Gastrointestinal: nausea, diarrhoea, constipation | Common | Usually mild and self-limited. |
| Adverse Effect | Reported Frequency | Clinical Note |
|---|---|---|
| Sleep disorders / disturbance | Most common | Most commonly reported AE in the Hemangeol paediatric trial; usually mild and not requiring discontinuation. |
| Worsening respiratory tract infections (bronchiolitis, bronchitis) | Common | Per the Hemangeol PI, treatment should be interrupted in the event of a lower respiratory tract infection associated with dyspnoea and wheezing. |
| Diarrhoea, vomiting | Common | Skip the dose if the infant is not feeding or is vomiting (hypoglycaemia risk); resume when feeding normally. |
| Bradycardia (mean ~7 bpm decrease) | Mean change in HF studies; severe bradycardia uncommon | Per the Hemangeol PI, discontinue treatment if severe bradycardia (<80 bpm) or symptomatic bradycardia or hypotension occurs. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Bronchospasm | Particular concern in patients with reactive airways disease — propranolol contraindicated in bronchial asthma | Within hours of dose | Inhaled β2-agonist (high-dose may be needed); discontinue propranolol; consider inhaled ipratropium and systemic corticosteroids if severe |
| Symptomatic bradycardia, sinus pause, AV block, cardiac arrest | Rare; risk higher with concomitant non-DHP CCB or in conduction disease | Hours to days after initiation or dose increase | Hold drug; atropine; transcutaneous or transvenous pacing for severe AV block; IV glucagon (3–10 mg) for refractory beta-blocker toxicity. Per the InnoPran XL PI, epinephrine may provoke uncontrolled hypertension and is not indicated for propranolol overdose |
| Severe rebound on abrupt withdrawal (ischaemia, MI, ventricular arrhythmia, thyroid storm in thyrotoxic patients) | Documented | Days after stopping | Avoid abrupt withdrawal; taper over 1–2 weeks; reinstitute promptly if rebound occurs |
| Severe / prolonged hypoglycaemia (especially in children, fasting patients, patients on insulin, perioperatively) | Greater concern with non-selective beta-blockers | During hypoglycaemic episodes | Counsel on non-adrenergic warning signs; in Hemangeol-treated infants, give doses with feeds and skip if not eating. Severe hypoglycaemia warrants emergency treatment |
| Anaphylaxis with relative resistance to adrenaline | Rare but particularly concerning with non-selective agents | Variable | Higher-dose adrenaline, IV glucagon (especially helpful for beta-blocker–related refractoriness), IV fluids, antihistamines, corticosteroids |
| Hypertensive crisis in unrecognised pheochromocytoma (without alpha-blockade) | Rare but predictable | Within hours | Always start alpha-blocker before any beta-blocker in suspected pheochromocytoma. If crisis occurs: IV phentolamine |
| Worsening peripheral arterial disease, Raynaud-type symptoms | Reported; non-selective agents are more likely to aggravate than cardioselective | Variable | Assess claudication and distal perfusion; consider switching to a vasodilating beta-blocker (carvedilol, nebivolol) if symptomatic |
| Heart failure exacerbation | Reported with abrupt initiation in HF | Days to weeks | Propranolol is NOT FDA-approved for chronic heart failure; metoprolol succinate, bisoprolol, or carvedilol are the evidence-based agents for this indication |
| Stroke (in PHACE syndrome) | Specific concern in infants with PHACE syndrome and severe cerebrovascular disease | Variable | Per the Hemangeol PI, lowering BP may increase stroke risk in PHACE syndrome patients with severe arteriopathy of the head and neck; screen large segmental facial haemangiomas for PHACE features |
| Hypersensitivity / anaphylactic-anaphylactoid reactions, agranulocytosis, thrombocytopenic and nonthrombocytopenic purpura (post-marketing) | Very rare | Variable | Discontinue; haematology assessment as appropriate |
| Cutaneous reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, urticaria (post-marketing) | Very rare | Variable | Permanent discontinuation; dermatology referral; supportive care |
| Drug-induced lupus / SLE-like reactions, psoriasiform rashes, alopecia (post-marketing) | Very rare | Months to years | Discontinuation usually leads to resolution |
| Sexual dysfunction (erectile dysfunction, decreased libido, Peyronie’s disease) | Reported in PI; class effect | Variable | Often underreported; consider switching to a vasodilating beta-blocker (nebivolol) if this becomes a barrier to adherence |
| Reason for Discontinuation | Relative Frequency | Context |
|---|---|---|
| Fatigue / exercise intolerance | Most common tolerability reason | Often improves over 2–4 weeks; consider dose reduction before discontinuation. |
| CNS effects (vivid dreams, depression, sleep disturbance) | More common than with cardioselective beta-blockers | Switching to atenolol or nadolol (less lipophilic) may resolve. |
| Bronchospasm | Particular concern in patients with reactive airways disease | Reactive airways disease is a contraindication to non-selective beta-blockers; switch to cardioselective (with caution) if absolutely necessary. |
| Worsening peripheral vascular disease, Raynaud’s symptoms, cold extremities | More common with non-selective agents | Switch to a vasodilating beta-blocker (nebivolol, carvedilol) if continuation is needed. |
| Sexual dysfunction | Common but underreported | Class effect; nebivolol may have a more favourable profile. |
Severe propranolol toxicity (intentional or accidental overdose, drug interaction, or hepatic impairment) presents with bradycardia, hypotension, AV block, bronchospasm, hypoglycaemia, seizures, and impaired consciousness. Critical management points: (1) IV glucagon (3–10 mg bolus, then infusion 2–5 mg/hour) is the most reliable antidote — it bypasses beta-receptor blockade and stimulates cardiac contractility via Gs-mediated cAMP. (2) Per the InnoPran XL PI, adrenaline should be used cautiously because beta-blockade with unopposed alpha-stimulation can provoke uncontrolled hypertension; isoproterenol or dobutamine (competitive β-agonists) may be more appropriate. (3) Atropine for bradycardia, transcutaneous pacing for severe AV block, IV fluids and vasopressors for hypotension. (4) Inhaled β2-agonists (potentially high doses) for bronchospasm; aminophylline if needed. (5) Propranolol is not significantly removed by haemodialysis.
Drug Interactions
Propranolol’s interaction profile is broader than that of cardioselective beta-blockers because it is metabolised by three CYP enzymes (CYP2D6, CYP1A2, CYP2C19) and because non-selective β-blockade has more pharmacodynamic interaction targets — particularly with adrenaline (vasoconstrictor crisis) and bronchodilators (β2 antagonism). Pharmacodynamic interactions are at least as clinically important as the pharmacokinetic ones.
(1) Adrenaline interaction — the most clinically dangerous: in patients on chronic propranolol who develop anaphylaxis, the usual adrenaline doses may be insufficient, and unopposed alpha-stimulation may cause hypertensive crisis. Have IV glucagon available. (2) Verapamil/diltiazem combination — the most common cardiology pitfall, particularly in atrial fibrillation rate control. (3) CYP1A2 dynamics with smoking — heavy smokers may need higher doses; smoking cessation can unmask elevated propranolol levels and excess bradycardia.
Monitoring
-
Heart Rate
Baseline, at each titration step, then at each follow-up
Routine Target resting HR generally 55–70 bpm depending on indication. For variceal prophylaxis, target ~25% reduction or HR ~55 bpm. For Hemangeol-treated infants, the PI specifies discontinuation if HR <80 bpm or symptomatic bradycardia. Monitor for 2 hours after the first Hemangeol dose and after each dose increase. -
Blood Pressure
Baseline, at each titration step, then at each follow-up
Routine Check both seated and standing. Symptomatic orthostasis or SBP <100 mmHg in adults, or SBP <50 mmHg in Hemangeol-treated infants, prompts dose reassessment. Continuous monitoring during IV propranolol administration. -
ECG
Baseline; repeat for symptomatic bradycardia or new conduction symptoms
Trigger-based Particularly important in patients with first-degree AV block, sinus node dysfunction, or conduction disorders (including Wolff-Parkinson-White, where propranolol may unmask severe bradycardia after termination of pre-excited tachycardia). -
Respiratory Symptoms
At each visit and at each dose escalation
Routine Particularly important given non-selective β2 blockade. Bronchial asthma is a contraindication to propranolol. In Hemangeol-treated infants, treatment should be interrupted during lower respiratory tract infections with dyspnoea or wheezing. -
Glycaemic Status (in diabetics; all Hemangeol patients)
Routinely in diabetics; symptom-guided in infants
Routine Non-selective beta-blockade impairs both adrenergic warning signs AND hepatic glucose mobilisation, increasing risk of severe and prolonged hypoglycaemia compared with cardioselective agents. For Hemangeol: give with feeds, skip if not feeding/vomiting, parents counselled on hypoglycaemia signs. -
Mood, Sleep, Cognitive Function
At each visit (open-ended enquiry)
Routine CNS effects (vivid dreams, depressive symptoms, impaired concentration, mental clouding) are more common with lipophilic non-selective propranolol than with hydrophilic agents. Switching to atenolol or nadolol may help. -
Sexual Function
At each follow-up (open-ended enquiry)
Routine Class effect, often underreported. Vasodilating beta-blockers (nebivolol) may have a more favourable profile if sexual dysfunction becomes a barrier to adherence. -
Peripheral Perfusion
At each visit if PVD or Raynaud’s history
Trigger-based Cold extremities are common; worsening claudication, new resting pain, or trophic skin changes warrant reassessment. -
PHACE Syndrome Screening (in infantile haemangioma patients)
Before initiating Hemangeol for large facial haemangiomas
Trigger-based Per the Hemangeol PI, propranolol-induced BP lowering may increase stroke risk in PHACE syndrome patients with severe arteriopathy of the head and neck. Imaging (MRI/MRA brain) is recommended for large segmental facial haemangiomas before initiation. -
Glaucoma Screening
Inform optometrist/ophthalmologist if relevant
Trigger-based Beta-blockade reduces intraocular pressure; per the Inderal PI, patients should be told that propranolol may interfere with glaucoma screening tests. -
Adherence
At each follow-up
Routine Particularly important because abrupt withdrawal — including from missed doses or running out of supply — can precipitate ischaemia in CAD, rebound hypertension, ventricular arrhythmia, or thyroid storm in thyrotoxic patients.
For routine adult propranolol monitoring, two vitals dominate: heart rate and blood pressure, checked at every titration step and at each follow-up. For Hemangeol-treated infants, the PI specifies 2 hours of HR and BP monitoring after the first dose and after each dose increase — this is a structured surveillance window that is non-negotiable. Once stable on maintenance dose with stable vitals, follow-up at 3–6 months is typically sufficient for adults; monthly (with weight-based dose adjustments) for Hemangeol over the 6-month treatment course.
Contraindications & Cautions
Absolute Contraindications (Adult Indications, per Inderal / Inderal XL PI)
- Cardiogenic shock
- Sinus bradycardia and greater than first-degree heart block (unless a permanent pacemaker is in place)
- Sick sinus syndrome (unless a permanent pacemaker is in place)
- Bronchial asthma — propranolol is a non-selective beta-blocker and is specifically contraindicated; this is a key distinction from cardioselective metoprolol or bisoprolol
- Known hypersensitivity (e.g., anaphylactic reaction) to propranolol hydrochloride or any of the components
Additional Hemangeol-Specific Contraindications (Per Hemangeol PI)
- Premature infants <5 weeks corrected gestational age
- Infants weighing <2 kg
- Asthma or history of bronchospasm
- Heart rate <80 bpm (for an infant)
- Greater than first-degree heart block
- Decompensated heart failure
- Blood pressure <50/30 mmHg
- Pheochromocytoma
- Hypersensitivity to propranolol or excipients
Relative Contraindications (Specialist Input Recommended)
- Severe peripheral vascular disease with critical limb ischaemia or rest pain — non-selective beta-blockade may exacerbate symptoms; consider a vasodilating beta-blocker (nebivolol, carvedilol)
- Prinzmetal (vasospastic) angina — unopposed alpha-mediated coronary vasoconstriction may worsen vasospasm; calcium channel blockers preferred
- Severe hepatic impairment — substantially elevated plasma exposure; if used, start at lower than usual dose
- Untreated pheochromocytoma — alpha-blocker must be initiated first; beta-blocker alone causes paradoxical hypertensive crisis
- Diabetes mellitus, particularly insulin-treated — non-selective beta-blockade increases hypoglycaemia risk more than cardioselective agents; cardioselective agent preferred unless propranolol-specific indication exists
- Pregnancy — not absolutely contraindicated and used when treatment is necessary, but crosses placenta; reports of intrauterine growth retardation, neonatal bradycardia, hypoglycaemia, and respiratory depression
- PHACE syndrome with severe cerebrovascular arteriopathy (in Hemangeol candidates) — relative contraindication due to stroke risk; case-by-case decision after imaging
Use with Caution
- Heart failure — propranolol is NOT FDA-approved for chronic heart failure; metoprolol succinate, bisoprolol, or carvedilol are the evidence-based agents. May be used cautiously when propranolol has a separate indication (e.g., post-MI, AF rate control)
- Mild–moderate COPD — generally avoid; if a beta-blocker is essential, choose a cardioselective agent at lowest dose
- Hyperthyroidism — useful for adrenergic symptom control but may mask tachycardia. Withdraw gradually after definitive thyroid therapy to avoid precipitating thyroid storm
- Anaphylaxis history — beta-blockade may blunt response to adrenaline used for treatment; have IV glucagon available
- Major surgery — abrupt withdrawal can precipitate perioperative myocardial ischaemia; continue chronic beta-blocker through the perioperative period whenever feasible. Avoid initiation of high-dose beta-blocker shortly before non-cardiac surgery in beta-blocker-naïve patients (POISE trial)
- Concurrent non-DHP calcium channel blocker therapy — additive AV nodal slowing
- Myasthenia gravis — may exacerbate muscle weakness
Propranolol does not carry an FDA boxed warning. The FDA prescribing information emphasises the risk of acute exacerbation of myocardial ischaemia or precipitation of MI on abrupt withdrawal in patients with known coronary disease — therapy should be tapered over 1–2 weeks rather than stopped suddenly. The PI also flags propranolol’s specific contraindication in bronchial asthma (a key distinction from cardioselective beta-blockers), warns that epinephrine should be used cautiously in propranolol overdose due to risk of unopposed alpha-stimulation and uncontrolled hypertension, and requires that an alpha-blocker be initiated before propranolol in pheochromocytoma to avoid paradoxical hypertensive crisis.
The Hemangeol PI further specifies a structured 2-hour monitoring window after the first dose and after each dose increase, mandates dose-skipping during fasting or vomiting (hypoglycaemia risk), and identifies stroke as a specific concern in PHACE syndrome with severe arteriopathy of the head and neck.
Patient Counselling
Purpose of Therapy
Explain that propranolol is a “beta-blocker” — one of the oldest and most versatile heart medications. Depending on what it is being prescribed for, it slows the heart, lowers blood pressure, prevents migraines, reduces hand tremor, calms physical anxiety symptoms (rapid heartbeat, shaking), or in infants treats a specific type of birthmark called an infantile haemangioma. Unlike newer beta-blockers (such as metoprolol), propranolol blocks both kinds of beta receptors in the body — making it more useful for some non-cardiac conditions but also more likely to cause cold hands, breathing issues in people with asthma, and sleep changes.
How to Take
Take propranolol exactly as prescribed. Immediate-release tablets are usually taken 2–4 times daily, ideally with or after meals. Long-acting capsules (Inderal LA, Inderal XL) are taken once daily. InnoPran XL extended-release is taken at bedtime, around 10 p.m., to time the medicine to reach peak levels in the morning. Long-acting capsules must be swallowed whole — do not crush, chew, or open them. Take it consistently, the same way each time. Do not stop suddenly. Stopping abruptly can cause chest pain, fast heart rate, rebound high blood pressure, and in people with heart disease can trigger a heart attack. In thyroid disease, sudden stopping can also trigger a thyroid storm. If you need to stop, your prescriber will guide you through a 1–2 week taper.
For Hemangeol (infantile haemangioma): Always give during or right after a feeding to reduce the risk of low blood sugar. Use the dosing syringe that came with the bottle — never a household spoon. Give two doses at least 9 hours apart. If your baby is not eating or is vomiting, skip the dose — do not catch up later. Throw the bottle away 2 months after first opening it. Keep your baby’s clinic appointments — the dose changes as your baby grows.
Sources
- U.S. Food and Drug Administration. Inderal (propranolol hydrochloride) tablets prescribing information. Akrimax Pharmaceuticals. FDA label PDF Primary source for immediate-release propranolol indications, dosing, contraindications, and adverse-event reporting across all approved adult indications including hypertension, angina, MI, arrhythmias, migraine, essential tremor, HOCM, and pheochromocytoma.
- U.S. Food and Drug Administration. Inderal LA (propranolol hydrochloride) long-acting capsules prescribing information. FDA label PDF Primary source for once-daily long-acting propranolol dosing in hypertension, angina, and migraine prophylaxis.
- U.S. Food and Drug Administration. Inderal XL (propranolol hydrochloride) extended-release capsules prescribing information. ANI Pharmaceuticals. DailyMed entry Source for the extended-release bedtime-dosing formulation; defines the upper dose ceiling of 120 mg/day for hypertension and the 80–120 mg dose strengths.
- U.S. Food and Drug Administration. InnoPran XL (propranolol hydrochloride) extended-release capsules prescribing information. FDA label PDF Source for adverse-event Table 1 (≥3% reporting threshold) and bedtime extended-release pharmacokinetics (Tmax 12–14 hours, half-life ~8 hours).
- U.S. Food and Drug Administration. Hemangeol (propranolol hydrochloride) oral solution prescribing information. Pierre Fabre. FDA label PDF Sole FDA-approved propranolol formulation for proliferating infantile haemangioma; defines age range (5 weeks to 5 months at initiation), weight-based dose escalation, and structured 2-hour monitoring requirements.
- Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735-746. DOI: 10.1056/NEJMoa1404710 Pivotal randomised controlled trial supporting Hemangeol approval — 460 infants with proliferating infantile haemangioma compared four propranolol regimens with placebo; the 3.4 mg/kg/day for 6 months regimen achieved 60% complete or near-complete resolution at week 24 versus 4% on placebo.
- Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651. DOI: 10.1056/NEJMc0708819 Original case-series observation that launched propranolol use in infantile haemangioma — the serendipitous discovery that propranolol given for cardiomyopathy caused dramatic regression of a coexisting facial haemangioma.
- β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA. 1982;247(12):1707-1714. DOI: 10.1001/jama.1982.03320370021023 BHAT trial — pivotal study supporting propranolol’s post-MI mortality reduction indication; demonstrated 26% reduction in total mortality over 25 months of follow-up.
- Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78(17):1337-1345. DOI: 10.1212/WNL.0b013e3182535d20 AAN/American Headache Society guideline classifying propranolol, metoprolol, and timolol as Level A (established as effective) for migraine prophylaxis.
- Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1):e20183475. DOI: 10.1542/peds.2018-3475 American Academy of Pediatrics guideline establishing oral propranolol as first-line therapy for problematic infantile haemangiomas requiring systemic treatment.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127-e248. DOI: 10.1016/j.jacc.2017.11.006 Beta-blockers including propranolol are not first-line for uncomplicated hypertension but are appropriate when there is a compelling indication.
- Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management — 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310-335. DOI: 10.1002/hep.28906 AASLD guidance defining the role of non-selective beta-blockers (propranolol, nadolol, carvedilol) in primary and secondary prophylaxis of variceal bleeding.
- Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. DOI: 10.1089/thy.2016.0229 ATA guidelines defining propranolol’s role in symptomatic management of hyperthyroidism and thyroid storm, including its weak inhibitory effect on peripheral T4-to-T3 conversion.
- Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic betareceptor antagonist. Lancet. 1964;1(7342):1080-1081. DOI: 10.1016/S0140-6736(64)91275-9 The original 1964 Lancet description of propranolol by Sir James Black and colleagues — the foundational publication that earned Black the 1988 Nobel Prize in Physiology or Medicine.
- Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163(2):269-274. DOI: 10.1111/j.1365-2133.2010.09848.x Reviews proposed mechanisms of propranolol’s effect on infantile haemangiomas — vasoconstriction, downregulation of VEGF and bFGF, and induction of capillary endothelial apoptosis.
- Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128-140. DOI: 10.1542/peds.2012-1691 Multidisciplinary consensus on practical aspects of propranolol initiation in infantile haemangioma — pretreatment evaluation, dosing, monitoring, and management of intercurrent illness — that informed the Hemangeol prescribing information.
- Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999;55(2):111-115. DOI: 10.1007/s002280050604 Mechanistic study explaining the well-recognised sleep disturbance with lipophilic beta-blockers including propranolol — beta-blockade suppresses pineal melatonin secretion.